NYSE · TMO
Healthcare · Medical - Diagnostics & Research
$617.10
Down-$5.08 (-0.82%)
Updated Sep 1, 2026, 9:20 AM
SID Score
7.1/10
Composite research score
Smart Money
55/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
TMO closed at $617.10 after 21 trading sessions, up 7.50% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 31, 2026 | $614.38 | $620.715 | $610.35 | $617.10 | 1.43M |
| Aug 28, 2026 | $626.58 | $630.00 | $617.45 | $622.18 | 1.02M |
| Aug 27, 2026 | $629.47 | $637.13 | $626.33 | $630.70 | 1.47M |
| Aug 26, 2026 | $622.23 | $636.06 | $622.23 | $633.71 | 1.84M |
| Aug 25, 2026 | $631.01 | $647.00 | $618.0303 | $628.15 | 1.54M |
| Aug 24, 2026 | $630.00 | $630.00 | $615.97 | $628.74 | 1.73M |
| Aug 21, 2026 | $626.48 | $629.51 | $616.27 | $629.27 | 1.56M |
| Aug 20, 2026 | $609.85 | $634.70 | $607.37 | $627.55 | 2.75M |
| Aug 19, 2026 | $595.11 | $620.475 | $594.995 | $613.54 | 2.51M |
| Aug 18, 2026 | $588.87 | $592.22 | $584.86 | $589.04 | 1.72M |
| Aug 17, 2026 | $582.55 | $592.32 | $580.00 | $585.51 | 887.3K |
| Aug 14, 2026 | $592.11 | $594.74 | $587.51 | $588.29 | 1.06M |
| Aug 13, 2026 | $606.29 | $606.75 | $593.39 | $595.89 | 1.45M |
| Aug 12, 2026 | $599.21 | $604.19 | $595.00 | $603.01 | 1.53M |
| Aug 11, 2026 | $599.99 | $606.21 | $594.81 | $605.00 | 1.66M |
| Aug 10, 2026 | $588.53 | $599.69 | $588.53 | $599.69 | 1.86M |
| Aug 7, 2026 | $578.00 | $594.26 | $574.7679 | $594.00 | 2.21M |
| Aug 6, 2026 | $576.80 | $580.31 | $569.63 | $580.02 | 1.72M |
| Aug 5, 2026 | $567.93 | $578.00 | $564.402 | $577.83 | 1.55M |
| Aug 4, 2026 | $578.76 | $582.3129 | $562.5001 | $564.75 | 1.94M |
| Aug 3, 2026 | $576.00 | $583.64 | $572.75 | $574.03 | 1.59M |
The latest Smart Investors Daily articles mentioning TMO.
TMO research
Company profile and research snapshot.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 27, 2026 | Morgan Stanley | Overweight | — |
| Jul 27, 2026 | Piper Sandler | Neutral | — |
| Jul 24, 2026 | Barclays | Overweight | — |
| Jul 24, 2026 | RBC Capital | Sector Perform | — |
| Jul 6, 2026 | Evercore ISI Group | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 26, 2026
Thermo Fisher Scientific (NYSE:TMO) has outperformed the market over the past 10 years by 1.87% on an annualized basis producing an average annual return of 15.26%. Currently, Thermo Fisher Scientific has a market
Benzinga · Aug 26, 2026
Experts recommend Delta, Thermo Fisher, Target, and Interactive Brokers Group, Inc. due to strong earnings and guidance.
Yahoo · Aug 22, 2026
Thermo Fisher Scientific (TMO) is drawing investor attention after completing Olink Explore HT proteomic analysis on about 5,500 samples from The Michael J. Fox Foundation’s Parkinson’s Precision Medicine Initiative. See our latest analysis for Thermo Fisher Scientific. The proteomics update arrives after a strong run in Thermo Fisher Scientific’s stock, with the share price at US$629.27 and a 30 day share price return of 19.53%, alongside a 1 year total shareholder return of 26.32% that...
Yahoo · Aug 22, 2026
The latest analyst work on Thermo Fisher Scientific includes a higher Fair Value Estimate that has moved from US$590.77 to US$631.42, a change of about 6.9% that feeds directly into refreshed price targets across coverage. This shift sits against a backdrop of mixed optimism and caution, as analysts weigh Q2 strength, sector updates through 2026, and the balance of growth ambition and execution risks. As you read on, you will see how this evolving narrative could shape the way you track...
Interpretive context generated from the platform’s current data sources.
Thermo Fisher Scientific Inc. shares closed at $617.10, reflecting a daily decline of approximately 1.05%, per SID market data. Despite the session's pullback, TMO has demonstrated positive momentum across multiple timeframes, gaining 7.45% over the past month and 24.91% over the trailing three months, according to Massive/Polygon data. The stock's one-year return stands at a more modest 7.28%, indicating that much of the recent appreciation has been concentrated in the near term. From a technical standpoint, TMO trades well above both its 50-day moving average of $560.53 and its 200-day moving average of $528.15, suggesting a sustained uptrend. The 14-day relative strength index reads 57.0, placing the stock in neutral territory without signaling overbought conditions. Average daily trading volume is approximately 2.05 million shares. The stock carries a beta of 0.902, indicating slightly lower volatility relative to the broader market.
Thermo Fisher Scientific currently commands a market capitalization of approximately $219.4 billion, positioning it among the largest companies in the Healthcare sector, per SID market data. The stock trades at a price-to-earnings ratio of 33.3, reflecting a premium valuation relative to broader market averages, according to SEC filings. The PEG ratio stands at an elevated 577.17, suggesting that the current earnings multiple is not well supported by near-term earnings growth expectations. TMO's price-to-book ratio of 4.29 indicates investors are paying a significant premium over the company's book value, consistent with the asset-light, high-margin profile typical of life sciences instrumentation businesses. The company offers a modest dividend yield of approximately 0.29%, signaling that capital return to shareholders is primarily directed elsewhere, likely share repurchases. Taken together, these metrics position TMO at a growth-premium valuation within the Healthcare sector landscape.
Thermo Fisher Scientific registers a composite smart money score of 55 out of 100 with a neutral overall signal, per SID market data. Institutional ownership sentiment is the strongest component, scoring a perfect 25 out of 25, indicating robust confidence among large asset managers. Congressional trading activity scores 11.6 out of 25, reflecting moderate legislative interest in the name. The insider trading component scores 9.7 out of 25, weighed down by a heavily sell-skewed transaction pattern. According to SEC Form 4 filings, there have been 20 insider trades over the past 90 days, comprising just 2 purchases against 18 sales. This pronounced imbalance suggests corporate insiders have been actively reducing personal exposure at current price levels. Dark pool activity scores 8.5 out of 25, indicating below-average off-exchange institutional accumulation. While institutional holders via 13F filings remain firmly committed, the insider selling cadence introduces a notable point of divergence within the smart money framework that warrants monitoring.
Thermo Fisher Scientific has delivered consecutive earnings beats in its two most recently reported quarters, according to company earnings reports. In the most recent quarter reported on July 23, 2026, the company posted earnings per share of $6.03, surpassing the consensus analyst estimate of $5.71 by $0.32, representing a positive surprise of approximately 5.6%. In the prior quarter reported on April 23, 2026, TMO earned $5.44 per share against estimates of $5.23, beating expectations by $0.21. Looking ahead, analysts project earnings of $5.71 per share for the upcoming quarter scheduled for July 22, 2026, and $5.29 per share for the quarter with results expected on April 22, 2026, per analyst estimates. The consistent pattern of outperformance suggests management execution has exceeded Wall Street modeling assumptions. The sequential acceleration in beat magnitude from $0.21 to $0.32 further underscores strengthening operational delivery.
Wall Street consensus on Thermo Fisher Scientific leans constructive, with the majority of recent analyst actions reaffirming positive or neutral stances, per Wall Street analyst reports. On July 27, 2026, Morgan Stanley reiterated its Overweight rating, while Piper Sandler maintained a Neutral position on the same date. Following the earnings release on July 24, both Barclays reiterated Overweight and RBC Capital maintained its Sector Perform rating. Earlier, on July 6, 2026, Evercore ISI Group reaffirmed its Outperform rating, according to SID consensus data. Of the five most recent analyst actions, three carry bullish-leaning ratings — two Overweight and one Outperform — while two maintain neutral stances. Notably, none of the recent coverage updates involved a rating change, with all five analysts holding their prior positions. This stability in analyst sentiment suggests the post-earnings fundamental picture has largely aligned with existing expectations, with no catalysts sufficient to prompt upgrades or downgrades across the coverage universe.
The latest Smart Investors Daily articles mentioning TMO.
